New data and analyses from the phase III ALSYMPCA trial of radium Ra 223 dichloride to be presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013

Not intended for US media Oslo, Norway, 12 September 2013 - Algeta ASA (OSE: ALGETA), announced today that further analyses of data subsets from the phase III ALSYMPCA study of radium Ra 223 dichloride (radium 223) will be presented at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), 28 September- 1 October, in Amsterdam, The Netherlands. Under the brand name Xofigo(®), radium 223 was approved by the US Food and Drug Administration (FDA) in May 2013 for the treatment of patients with castration- resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease and is now available in the United States at licensed facilities. Dr Gillies O'Bryan-Tear, Algeta's Chief Medical Officer, said: "These data add further to our understanding of the efficacy and safety profile of radium 223 in prostate cancer patients with bone metastases, and highlight both the depth and breadth of the ALSYMPCA phase III data set." Abstract titles and session details Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis * Abstract #2876, Poster Session: Genitourinary Malignancies - Prostate Cancer * Monday, 30 September, 9:30 AM-12:00 PM CEST, Hall 4 Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: baseline prognostic factor subgroup analysis * Abstract #2877, Poster Session: Genitourinary Malignancies - Prostate Cancer * Monday, 30 September, 9:30 AM-12:00 PM CEST, Hall 4 Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration- resistant prostate cancer (CRPC) and bone metastases * Abstract #2878, Poster Session: Genitourinary Malignancies - Prostate Cancer * Monday, 30 September, 9:30 AM-12:00 PM CEST, Hall 4 Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration- resistant prostate cancer (CRPC) with bone metastases: phase 3 ALSYMPCA study findings stratified by age group * Abstract #2883, Poster Session: Genitourinary Malignancies - Prostate Cancer * Monday, 30 September, 9:30 AM-12:00 PM CEST, Hall 4 About radium Ra 223 dichloride Radium-223 dichloride (radium 223) is currently not approved by the European Medicines Agency (EMA) or other authorities outside the US. Bayer submitted a Marketing Authorisation Application to the EMA for radium 223 in December 2012 and subsequently in other territories. Radium 223 (as Xofigo(®) injection) is approved in the United States and is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Radium 223 is an alpha particle-emitting radioactive therapeutic agent with an anti-tumor effect on bone metastases. The active ingredient in radium 223 is the alpha particle-emitting isotope radium-223, which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The high linear energy transfer of radium- 223 may cause double-strand DNA breaks in adjacent cells, resulting in an anti- tumor effect on bone metastases. The alpha particle range from radium-223 is less than 100 micrometers which may limit the damage to the surrounding normal tissue[1]. In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of radium 223. Under the terms of the agreement, Bayer will develop, apply for health authority approvals worldwide and commercialize Xofigo globally. Algeta is eligible for royalties and milestones based on Bayer's sales of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer in the US. For full US prescribing information, visit www.xofigo-us.com. ### Xofigo(®) is a registered trademark of Bayer For further information, please contact: Mike Booth +44 7866 490 850 Communications & Corporate Affairs ir@algeta.com Media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton knut.ekern@hkstrategies.com Investor enquiries: Tricia Truehart +1 646 378 2953 The Trout Group ttruehart@troutgroup.com About Algeta Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com. Forward-looking Statements This news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Algeta. Such forward-looking statements reflect our current views and are based on the information currently available to Algeta. Algeta cannot give any assurance as to whether such forward looking statements will prove to be correct. These forward looking statements include statements regarding our co-promotion of Xofigo in the US and Bayer's promotion of Xofigo in Europe. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, general economic and business conditions, the impact of competition, the ability to successfully commercialize Xofigo, the risk that costs associated with the co-promotion of Xofigo may be greater than anticipated, manufacturing capacity, risks in obtaining additional regulatory approvals for radium 223 and the other risks and uncertainties described in our annual report. [1] XOFIGO Prescribing information. May 2013 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Press release: http://hugin.info/134655/R/1728746/577439.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Algeta ASA via Thomson Reuters ONE [HUG#1728746]